Based in Seattle, Resolve Therapeutics is developing a biologic compound called RSLV-125 that inhibits a key step in the interferon cascade, with the aim of improving the lives of patients suffering from Systemic Lupus Erythematosus (SLE). The company is leveraging pioneering discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, and has exclusive licenses for the technology and compounds from the university. Resolve Therapeutics plans to advance RSLV-125 from preclinical research through a phase IIa clinical trial, and eventually partner with a pharmaceutical company for late-stage clinical development and commercialization.